BioSpace News Archive

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2019.

Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced that its next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder (OAB).

TCR2 Therapeutics Inc. announced that preclinical data on its lead solid tumor program TC-210 and its lead blood cancer program TC-110 will be presented at the American Association for Cancer Research Annual Meeting 2019.

Dr. Bluestone is a World-renowned Expert and Academic Leader in Immune Tolerance Research

Pre-clinical and human compassionate use clinical evidence support IND filing mid-year 2019

Phio Pharmaceuticals Corp. announced that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio’s self-delivering RNAi technology in combination with Glycostem’s proprietary Natural Killer-cell generation technology to develop cellular immunotherapies for cancer treatment with enhanced efficacy and/or safety.

Tricida, Inc. announced financial results for the three months and full year ended December 31, 2018 and provided an update on key initiatives.

Viking Therapeutics, Inc. announced that the company will participate in two upcoming investor conferences.

GenScript®, the world’s leading gene synthesis provider, announced that it will provide funding and DNA synthesis expertise toward a project at Harvard University to generate the first comprehensive, renewable library of Drosophila recombinant antibodies.

Liberty to provide sophisticated cannabis terpene technology to Florida patients